{"DataElement":{"publicId":"2188254","version":"1","preferredName":"Concomitant Agent Administered Type","preferredDefinition":"the type of concomitant agent administered.","longName":"CONCOM_AGT_ADM_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2188255","version":"1","preferredName":"Concomitant Agent Administered","preferredDefinition":"information related to the concomitant agent administered.","longName":"CONCOMITANT_AGT_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206526","version":"1","preferredName":"Concomitant Agent","preferredDefinition":"Concomitant; following as a consequence.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C25730:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant","conceptCode":"C25730","definition":"Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F886-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3A85A88-8AD2-1E4D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2188253","version":"1","preferredName":"Concomitant Agent Administered Type","preferredDefinition":"the type of concomitant agent administered.","longName":"CONCOM_AGT_ADM_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Dexamethasone","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"2568530","version":"1","preferredName":"Dexamethasone","longName":"2568530v1.00","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8BF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E398CDB8-043B-4C1F-E034-0003BA12F5E7","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-08","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E398CDB8-043E-4C1F-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-08","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Darbepoetin alfa","valueDescription":"Darbepoetin Alfa","ValueMeaning":{"publicId":"2577851","version":"1","preferredName":"Darbepoetin Alfa","longName":"2577851","preferredDefinition":"A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein.  Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin.  Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darbepoetin Alfa","conceptCode":"C1878","definition":"A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein.  Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin.  Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD28-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1F2A04B4-4543-1ED5-E044-0003BA3F9857","beginDate":"2006-10-06","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-06","modifiedBy":"ONEDATA","dateModified":"2006-10-06","deletedIndicator":"No"},{"value":"Medication no longer being taken","valueDescription":"Medication no longer being taken","ValueMeaning":{"publicId":"2733092","version":"1","preferredName":"Medication no longer being taken","longName":"2733092","preferredDefinition":"Medication no longer being taken","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"479C87AC-21BB-03EF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"SHIDED","dateCreated":"2008-03-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"479C87AC-21D4-03EF-E044-0003BA3F9857","beginDate":"2008-03-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-03-04","modifiedBy":"SHIDED","dateModified":"2008-03-04","deletedIndicator":"No"},{"value":"New medication","valueDescription":"Addition of new medication","ValueMeaning":{"publicId":"2569355","version":"1","preferredName":"Addition of new medication","longName":"2569355","preferredDefinition":"Addition of new medication","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DBF8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-04-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-04-22","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"479C87AC-21E9-03EF-E044-0003BA3F9857","beginDate":"2008-03-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-03-04","modifiedBy":"SHIDED","dateModified":"2008-03-04","deletedIndicator":"No"},{"value":"Atezolizumab","valueDescription":"Atezolizumab","ValueMeaning":{"publicId":"5242662","version":"1","preferredName":"Atezolizumab","longName":"5242662","preferredDefinition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atezolizumab","conceptCode":"C106250","definition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-9907-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6AF3-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"Avelumab","valueDescription":"Avelumab","ValueMeaning":{"publicId":"5799363","version":"1","preferredName":"Avelumab","longName":"5799363","preferredDefinition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Avelumab","conceptCode":"C116870","definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E757D46-6B00-5282-E053-F662850AE968","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6B19-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"Durvalumab","valueDescription":"Durvalumab","ValueMeaning":{"publicId":"5755432","version":"1","preferredName":"Durvalumab","longName":"5755432","preferredDefinition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Durvalumab","conceptCode":"C103194","definition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CFD0718-5F32-7D12-E053-F662850AD37E","latestVersionIndicator":"Yes","beginDate":"2017-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6B23-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"GM-CSF","valueDescription":"Granulocyte-Macrophage Colony-Stimulating Factor","ValueMeaning":{"publicId":"5799364","version":"1","preferredName":"Granulocyte-Macrophage Colony-Stimulating Factor","longName":"5799364","preferredDefinition":"Granulocyte-macrophage colony-stimulating factor (144 aa, ~16 kDa) is encoded by the human CSF2 gene. This protein plays a role in the positive regulation of the growth and differentiation of cells in the granulocyte, macrophage, eosinophil and erythrocyte lineages.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granulocyte-Macrophage Colony-Stimulating Factor","conceptCode":"C20545","definition":"Granulocyte-macrophage colony-stimulating factor (144 aa, ~16 kDa) is encoded by the human CSF2 gene. This protein plays a role in the positive regulation of the growth and differentiation of cells in the granulocyte, macrophage, eosinophil and erythrocyte lineages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E757D46-6B2F-5282-E053-F662850AE968","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6B48-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"IL-2","valueDescription":"Recombinant Interleukin-2","ValueMeaning":{"publicId":"5799366","version":"1","preferredName":"Recombinant Interleukin-2","longName":"5799366","preferredDefinition":"One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. Interleukin-2 is made by a type of T lymphocyte. It increases the growth and activity of other T lymphocytes and B lymphocytes, and affects the development of the immune system. Aldesleukin (interleukin-2 made in the laboratory) is being used as a biological response modifier to boost the immune system in cancer therapy. Interleukin-2 is a type of cytokine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Interleukin-2","conceptCode":"C587","definition":"Any recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. IL-2 binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E757D46-6B55-5282-E053-F662850AE968","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6B6E-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"IL-15","valueDescription":"Interleukin-15","ValueMeaning":{"publicId":"5799367","version":"1","preferredName":"Interleukin-15","longName":"5799367","preferredDefinition":"Interleukin-15 (162 aa, ~18 kDa) is encoded by the human IL15 gene. This protein plays a role in the regulation of both proliferation and activation of both T-cells and natural killer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-15","conceptCode":"C20517","definition":"Interleukin-15 (162 aa, ~18 kDa) is encoded by the human IL15 gene. This protein plays a role in the regulation of both proliferation and activation of both T-cells and natural killer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E757D46-6B78-5282-E053-F662850AE968","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6B90-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"Ipilimumab","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6B9B-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"Lenalidomide","valueDescription":"Lenalidomide","ValueMeaning":{"publicId":"3379210","version":"1","preferredName":"Lenalidomide","longName":"3379210","preferredDefinition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B2FA-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6BA5-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":"Nivolumab","ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6BAF-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"Pembrolizumab","valueDescription":"Pembrolizumab","ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6BB9-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"},{"value":"Pomalidomide","valueDescription":"Pomalidomide","ValueMeaning":{"publicId":"3944871","version":"1","preferredName":"Pomalidomide","longName":"3944871","preferredDefinition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pomalidomide","conceptCode":"C72560","definition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F055-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E757D46-6BC3-5282-E053-F662850AE968","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"ONEDATA","dateModified":"2017-05-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E398B9D5-00DB-4C21-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-09-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-08","modifiedBy":"CAMPBELB","dateModified":"2017-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811835","version":"1","longName":"Melanoma","context":"CTEP"},{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685478","version":"1","longName":"Testing Set – Moderately Different","context":"NCIP"}]}],"AlternateNames":[{"name":"CTI_COTH_concomitant_drg_type","type":"NMDP_FN","context":"NHLBI"},{"name":"NHLBI","type":"USED_BY","context":"NHLBI"},{"name":"PerformedSubstanceAdministration:value","type":"HCT_BRIDG_5","context":"CTEP"},{"name":"CTI_DRTH_concomitant_drg_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Concomitant medications admin","type":"Preferred Question Text","description":"Concomitant medications administered during this cycle","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Concomitant Medication Reason","url":null,"context":"CTEP"},{"name":"Specify drugs","type":"Alternate Question Text","description":"Specify drugs","url":null,"context":"NHLBI"},{"name":"Specify drugs","type":"Application Standard Question Text","description":"Specify drugs","url":null,"context":"NHLBI"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E398CAF4-861A-4C23-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-09-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-08","modifiedBy":"MALUMK","dateModified":"2021-04-16","changeDescription":"Added HCT_BRIDG5 alternate name - RR 2018-12-23","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}